CAS NO: | 502487-67-4 |
生物活性 | SQ109 is a potent inhibitor of thetrypomastigoteform of theparasite, withIC50for cell killing of 50±8 nM. SQ109, targetsMmpL3, is an antitubercular agent. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | SQ109 also inhibits extracellular epimastigotes (IC50, 4.6±1 μM) and the clinically relevant intracellular amastigotes (IC50, ~0.5 to 1 μM), with a selectivity index of ~10 to 20. SQ109 has little effect (EC50, ~80 μM) in a red blood cell hemolysis assay. Besides, SQ109 causes major ultrastructural changes in all three life cycle forms, as observed by light microscopy, scanning electron microscopy (SEM), and transmission electron microscopy (TEM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Oral administration of SQ109 (0.1-25 mg/kg per day) to the mice for 28 days results in dose-dependent reductions of mycobacterial load in both spleen and lung comparable to that of EMB administered at 100 mg/kg per day, but is less potent than isoniazid (INH) at 25 mg/kg per day. Pharmacokinetic profiles of SQ109 in mice following a single administration showed its Cmaxas 1038 (intravenous (i.v.)) and 135 ng/mL (p.o.), with an oral Tmaxof 0.31 h. The elimination t1/2of SQ109 is 3.5 (i.v.) and 5.2 h (p.o.). The oral bioavailability is 4%[2]. The terminal half-life (t1/2) of SQ109 in dogs (12-29 h, mean 29.3 h) is longer than in rats (7-8 h, mean 7.4 h), as reflected by the significantly larger volume of distribution of SQ109 in dogs. The oral bioavailability of SQ109 in rats and dogs is determined to be 12% and 5%, respectively[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 330.55 | ||||||||||||||||
性状 | Liquid | ||||||||||||||||
Formula | C22H38N2 | ||||||||||||||||
CAS 号 | 502487-67-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 25 mg/mL(75.63 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |